Iktos and Astrogen Announce a Research Collaboration to Use Artificial Intelligence Platform for Drug Design against a Novel Parkinson’s Disease Target
Retrieved on:
Wednesday, January 5, 2022
Other Health, Software, Research, Data Management, Mental Health, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Time, Drug discovery, Autism spectrum, Intelligence, Analysis, AI, Artificial intelligence, Software, Astrogenes, Lists of diseases, Business, ASD, Parkinson's disease, Drug design, Software as a service, CEO, Business development, Technology, Solution, Deep learning, De novo, Pharmaceutical industry, Ikto!: 20 Megales Epitihies Tou, Iktos, Astrogen, IKTOS, ASTROGEN
Astrogen will contribute to in-vitro/in-vivo efficacy screening of lead compounds/pre-clinical drug candidates and will lead the entire development process from pre-clinical stage.
Key Points:
- Astrogen will contribute to in-vitro/in-vivo efficacy screening of lead compounds/pre-clinical drug candidates and will lead the entire development process from pre-clinical stage.
- The companies will share responsibility for generating lead compounds and pursuing the optimal development path for selecting pre-clinical drug candidates.
- We are proud and excited to announce our first collaboration deal in S. Korea bio-pharma sector commented Yann Gaston-Math, President and CEO of Iktos.
- We are very pleased to collaborate with Iktos, one of the leading AI companies in drug design and discovery.